Drug-induced liver injury associated with Complementary and Alternative Medicine: A review of adverse event reports in an Asian community from 2009 to 2014

BMC Complementary and Alternative Medicine

Volumn 16, Issue 1, 2016, Pages

  Teo, Desmond Chun Hwee ^a   Ng, Patricia Suet Leng ^b   Tan, Siew Har ^b   Lim, Adena Theen ^b   Toh, Dorothy Su Lin ^b   Chan, Sui Yung ^a   Cheong, Han Hui ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b HEALTH SCIENCES AUTHORITY   (Singapore)

^c KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

Author keywords

Adverse event; Complementary and Alternative Medicine; Hepatotoxicity; Traditional Chinese Medicine

Indexed keywords

ALISMA ORIENTALIS EXTRACT; ANGELICA PUBESCENTIS EXTRACT; ATRACTYLODES EXTRACT; BUPLEURUM ROOT EXTRACT; DICTAMNI CORTEX EXTRACT; EPHEDRA SINICA EXTRACT; GLYCYRRHIZA EXTRACT; HERBACEOUS AGENT; LIGUSTICUM CHUANXIONG EXTRACT; PINELLIA EXTRACT; POLYGONUM CUSPIDATUM EXTRACT; POLYGONUM MULTIFLORUM EXTRACT; PORIA COCOS EXTRACT; RHUBARB EXTRACT; SCUTELLARIA BAICALENSIS EXTRACT; SEMEN CASSIAE EXTRACT; TOOSENDAN EXTRACT; TRICHOSANTHES EXTRACT; UNCLASSIFIED DRUG; XANTHII SIBIRICI EXTRACT;

ACUTE HEPATITIS; ALTERNATIVE MEDICINE; ARTICLE; ASIAN; CHINESE MEDICINE; CHOLESTASIS; CHOLESTATIC HEPATITIS; CHRONIC HEPATITIS; DATA ANALYSIS; DEMOGRAPHY; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FATTY LIVER; HOSPITALIZATION; HUMAN; HYPERTRANSAMINASEMIA; INFORMATION PROCESSING; LACTIC ACIDOSIS; LIVER ADENOMA; LIVER CELL CARCINOMA; LIVER FOCAL NODULAR HYPERPLASIA; LIVER NECROSIS; LIVER VENOOCCLUSIVE DISEASE; MEDICAL ASSESSMENT; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; RISK BENEFIT ANALYSIS; SINGAPORE; TOXIC HEPATITIS; WESTERN MEDICINE; ADOLESCENT; ADULT; ADVERSE EFFECTS; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHILD; FEMALE; INFANT; MALE; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHILD; CHILD, PRESCHOOL; COMPLEMENTARY THERAPIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SINGAPORE; YOUNG ADULT;

EID: 84978842086     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/s12906-016-1168-z     Document Type: Article

References (70)

1. National Center for Complementary and Alternative Medicine. Complementary, Alternative, or Integrative Health: What's In a Name? [ http://nccam.nih.gov/health/whatiscam ]. Accessed 9 Mar 2015.
2. WHO. Traditional Medicine Strategy: 2002-2005. Geneva, Switzerland: World Health Organisation; 2002. Last Updated 7 Oct 2014. [ http://apps.who.int/medicinedocs/en/d/Js2297e/ ] Accessed 9 Mar 2015.
3. Rahman S, Singhal K. Problems in pharmacovigilance of medicinal products of herbal origin and means to minimize them. Uppsala Reports. 2002;17(Suppl):1-4.
4. Ernst E. Prevalence of use of complementary/alternative medicine: a systematic review. Bull World Health Organ. 2000;78(2):258-66.
5. Frass M, Strassl RP, Friehs H, Mullner M, Kundi M, Kaye AD. Use and acceptance of complementary and alternative medicine among the general population and medical personnel: a systematic review. Ochsner J. 2012;12(1):45-56.
6. Harris P, Rees R. The prevalence of complementary and alternative medicine use among the general population: a systematic review of the literature. Complement Ther Med. 2000;8(2):88-96.
7. Al-Windi A. Determinants of complementary alternative medicine (CAM) use. Complement Ther Med. 2004;12(2-3):99-111.
8. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer. 1998;83(4):777-82.
9. Pan CX, Morrison RS, Ness J, Fugh-Berman A, Leipzig RM. Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life. A systematic review. J Pain Symptom Manage. 2000;20(5):374-87.
10. Bishop FL, Prescott P, Chan YK, Saville J, von Elm E, Lewith GT. Prevalence of complementary medicine use in pediatric cancer: a systematic review. Pediatrics. 2010;125(4):768-76.
11. Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, Hirai M, Nakano T, Takashima S. Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol. 2005;23(12):2645-54.
12. Coulter ID, Willis EM. The rise and rise of complementary and alternative medicine: a sociological perspective. Med J Aust. 2004;180(11):587-9.
13. Ernst E. The role of complementary and alternative medicine. BMJ. 2000;321(7269):1133-5.
14. Xu KT. Socioeconomic aspects of the use of complmentary and alternative medicine. In: Watson RR, editor. Complementary and Alternative Therapies and the Aging Population: An Evidence-Based Approach. United States of America: Academic; 2009. p. 275-98.
15. Ayers SL, Kronenfeld JJ. Delays in seeking conventional medical care and complementary and alternative medicine utilization. Health Serv Res. 2012;47(5):2081-96.
16. Health Sciences Authority. Complementary Health Products: Overview. [ http://www.hsa.gov.sg/content/hsa/en/Health_Products_Regulation/Complementary_Health_Products/Overview.html ]. Accessed 9 Mar 2015.
17. Lim MK, Sadarangani P, Chan HL, Heng JY. Complementary and alternative medicine use in multiracial Singapore. Complement Ther Med. 2005;13(1):16-24.
18. The statutes of the Republic of Singapore: Medicines Act, Chapter 176, Original Enactment: Act 52 of 1975 (Revised Ed. 1985). 1987.
19. Health Sciences Authority. Chinese Proprietary Medicines. [ http://www.hsa.gov.sg/content/hsa/en/Health_Products_Regulation/Complementary_Health_Products/Chinese_Proprietary_Medicines/Overview/Regulatory_Framework.html ]. Accessed 9 Mar 2015.
20. Harris PE, Cooper KL, Relton C, Thomas KJ. Prevalence of complementary and alternative medicine (CAM) use by the general population: a systematic review and update. Int J Clin Pract. 2012;66(10):924-39.
21. Patel DN, Low WL, Tan LL, Tan MM, Zhang Q, Low MY, Chan CL, Koh HL. Adverse events associated with the use of complementary medicine and health supplements: an analysis of reports in the Singapore pharmacovigilance database from 1998 to. Clin Toxicol(Phila) 2012. 2009;50(6):481-9.
22. Wai CT. Presentation of drug-induced liver injury in Singapore. Singapore Med J. 2006;47(2):116-20.
23. Wai CT, Tan BH, Chan CL, Sutedja DS, Lee YM, Khor C, Lim SG. Drug-induced liver injury at an Asian center: a prospective study. Liver Int. 2007;27(4):465-74.
24. Raschi E, De Ponti F. Drug- and herb-induced liver injury: progress, current challenges and emerging signals of post-marketing risk. World J Hepatol. 2015;7(13):1761-71.
25. Teschke R, Schwarzenboeck A, Eickhoff A, Frenzel C, Wolff A, Schulze J. Clinical and causality assessment in herbal hepatotoxicity. Expert Opin Drug Saf. 2013;12(3):339-66.
26. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11(2):272-6.
27. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323-30.
28. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46(11):1331-6.
29. Garcia-Cortes M, Stephens C, Lucena MI, Fernandez-Castaner A, Andrade RJ. Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol. 2011;55(3):683-91.
30. Garcia-Cortes M, Lucena MI, Andrade RJ, Camargo R, Alcantara R. Is the Naranjo probability scale accurate enough to ascertain causality in drug-induced hepatotoxicity? Ann Pharmacother. 2004;38(9):1540-1.
31. Teschke R, Schulze J. Suspected herbal hepatotoxicity: requirements for appropriate causality assessment by the US pharmacopeia. Drug Saf. 2012;35(12):1091-7.
32. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001;33(1):123-30.
33. WHO Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems [ http://apps.who.int/medicinedocs/en/m/abstract/Js7148e/ ] Last Updated 2014. Accessed 9 Mar 2015.
34. Diseases NIDDK: LiverTox Database. In.: National Institue of Diabetes and Digestive and Kidney Diseases. [ http://livertox.nih.gov ]. Accessed 4 Mar 2015.
35. Liss G, Lewis JH. Drug-induced liver injury: what was new in 2008? Expert Opin Drug Metab Toxicol. 2009;5(8):843-60.
36. Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol. 2008;66(6):758-66.
37. Itoh S, Marutani K, Nishijima T, Matsuo S, Itabashi M. Liver injuries induced by herbal medicine, Syo-saiko-to (xiao-chai-hu-tang). Dig Dis Sci. 1995;40(8):1845-8.
38. Drew AK, Whyte IM, Bensoussan A, Dawson AH, Zhu X, Myers SP. Chinese herbal medicine toxicology database: monograph on Herba Asari, "xi xin". J Toxicol Clin Toxicol. 2002;40(2):169-72.
39. Stedman C. Herbal hepatotoxicity. Semin Liver Dis. 2002;22(2):195-206.
40. Barnes J. Pharmacovigilance of herbal medicines: a UK perspective. Drug Saf. 2003;26(12):829-51.
41. Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349(5):474-85.
42. Stickel F, Patsenker E, Schuppan D. Herbal hepatotoxicity. J Hepatol. 2005;43(5):901-10.
43. Hsu L-M, Huang Y-S, Tsay S-H, Chang F-Y, Lee S-D. Acute hepatitis induced by Chinese hepatoprotective herb, Xiao-Chai-Hu-Tang. J Chin Med Assoc. 2006;69(2):86-8.
44. Leung AY. Traditional toxicity documentation of Chinese Materia Medica - An overview. Toxicol Pathol. 2006;34(4):319-26.
45. Khan S, Khan I, Walker L: Botanical supplements and hepatotoxicity. In: Hepatotoxicity. edn. Chichester, UK: John Wiley & Sons, Ltd; 2008: 589-606.
46. Navarro VJ. Herbal and dietary supplement hepatotoxicity. Semin Liver Dis. 2009;29(04):373-82.
47. Teschke R, Wolff A, Frenzel C, Schulze J, Eickhoff A. Herbal hepatotoxicity: a tabular compilation of reported cases. Liver Int. 2012;32(10):1543-56.
48. Teschke R, Frenzel C, Glass X, Schulze J, Eickhoff A. Herbal hepatotoxicity: a critical review. Br J Clin Pharmacol. 2013;75(3):630-6.
49. Ma X, Peng JH, Hu YY. Chinese Herbal Medicine induced Liver Injury. J Clin Transl Hepatol. 2014;2(3):170-5.
50. Navarro VJ, Lucena MI. Hepatotoxicity induced by herbal and dietary supplements. Semin Liver Dis. 2014;34(2):172-93.
51. Wang G-Q, Deng Y-Q, Hou F-Q. Overview of drug-induced liver injury in China. Clin Liver Dis. 2014;4(1):26-9.
52. Björnsson ES. Drug-induced liver injury: An overview over the most critical compounds. Arch Toxicol. 2015;89(3):327-34.
53. Stickel F, Shouval D. Hepatotoxicity of herbal and dietary supplements: an update. Arch Toxicol. 2015;89(6):851-65.
54. Kando JC, Yonkers KA, Cole JO. Gender as a risk factor for adverse events to medications. Drugs. 1995;50(1):1-6.
55. Miller MA. Gender-based differences in the toxicity of pharmaceuticals--the Food and Drug Administration's perspective. Int J Toxicol. 2001;20(3):149-52.
56. Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138(7):2246-59.
57. Knell ME. Adverse reactions. In: Pharmaceutical Care with Dietary Supplements: Concepts and Common Sense. edn. Edited by McQueen CE. Bethesda: American Society of Health-System Pharmacists; 2006: 79-112.
58. Walker A. The relation between voluntary notification and material risk in dietary supplement safety. United States of America: Food And Drug Administration Commissioned Paper; 2000. FDA Docket 00N-1200.
59. Chow WH, Chang P, Lee SC, Wong A, Shen HM, Verkooijen HM. Complementary and alternative medicine among Singapore cancer patients. Ann Acad Med Singapore. 2010;39(2):129-35.
60. Shih V, Chiang JY, Chan A. Complementary and alternative medicine (CAM) usage in Singaporean adult cancer patients. Ann Oncol. 2009;20(4):752-7.
61. Seeff LB. Herbal hepatotoxicity. Clin Liver Dis. 2007;11(3):577-96. vii.
62. Teschke R, Lebot V. Proposal for a kava quality standardization code. Food Chem Toxicol. 2011;49(10):2503-16.
63. Health Sciences Authority. Guidelines on CPM Product Listing. [ http://www.hsa.gov.sg/content/hsa/en/Health_Products_Regulation/Complementary_Health_Products/Chinese_Proprietary_Medicines/Overview/Guidelines_for_CPM/guidelines-on-cpm-product-listing-.html ]. Accessed 9 Mar 2015.
64. Posadzki P, Watson LK, Ernst E. Adverse effects of herbal medicines: an overview of systematic reviews. Clin Med(Lond). 2013;13(1):7-12.
65. Ernst E. Herbal remedies for anxiety - a systematic review of controlled clinical trials. Phytomedicine. 2006;13(3):205-8.
66. Ernst E, Pittler MH. Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. Br J Anaesth. 2000;84(3):367-71.
67. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med. 2002;137(10):805-13.
68. Long L, Soeken K, Ernst E. Herbal medicines for the treatment of osteoarthritis: a systematic review. Rheumatology (Oxford). 2001;40(7):779-93.
69. Vogler BK, Pittler MH, Ernst E. The efficacy of ginseng. A systematic review of randomised clinical trials. Eur J Clin Pharmacol. 1999;55(8):567-75.
70. Kamsu-Foguem B, Foguem C. Adverse drug reactions in some African herbal medicine: literature review and stakeholders' interview. Integr Med Res. 2014;3(3):126-32.